Deepan Dalal, MD
Rheumatology · Cranston, RINPI 1962720441
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Johnson & Johnson at 56.1% of the total. Among rheumatology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 824 payments — averaging $148.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$68K
- AbbVie$15K
- Boehringer Ingelheim$9K
- Janssen Scientific Affairs, LLC$8K
- Amgen$8K
- Pfizer$4K
- plus $9K from 27 others
What the payments were for
- Consulting fees$23,99520%
- Speaking & faculty fees$69,07357%
- Travel & lodging$11,3679%
- Food & beverage$16,96714%
- Education$6351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 146 | $68,494 |
| AbbVie | 144 | $14,846 |
| Boehringer Ingelheim | 11 | $8,923 |
| Janssen Scientific Affairs, LLC | 13 | $8,148 |
| Amgen(2 entities) | 131 | $7,718 |
| Pfizer | 47 | $4,493 |
| Merck | 6 | $2,900 |
| UCB, Inc. | 95 | $1,751 |
| AstraZeneca | 60 | $1,450 |
| GSK | 50 | $654 |
| Mallinckrodt Hospital Products Inc. | 23 | $631 |
| Sobi, Inc | 18 | $353 |
| Genentech USA, Inc. | 12 | $313 |
| Lilly USA, LLC | 13 | $243 |
| Sanofi | 8 | $173 |
| Organon | 10 | $165 |
| Novartis | 6 | $132 |
| Fresenius Kabi USA, LLC | 6 | $118 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| ANI Pharmaceuticals, Inc. | 3 | $89 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $58 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $43 |
| Aurinia Pharma U.S., Inc. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Cumberland Pharmaceuticals, Inc. | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Invivyd Inc | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Tonix Medicines, Inc. | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $18 |
| Sandoz | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$122,037 in reported general payments places this provider in the 90th percentile of 22 rheumatology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 68 | $538,960 |
| EnbrelEtanercept | 26 | $191,194 |
| Enbrel MiniEtanercept | 23 | $177,350 |
| Enbrel SureclickEtanercept | 12 | $99,652 |
| Actemra ActpenTocilizumab | 13 | $60,479 |
| Hydroxychloroquine Sulfate | 469 | $22,086 |
| Mycophenolate Mofetil | 32 | $7,883 |
| MethotrexateMethotrexate Sodium | 319 | $7,281 |
| Methylprednisolone | 273 | $7,177 |
| Leflunomide | 55 | $4,349 |
| Prednisone | 578 | $4,149 |
| Colchicine | 56 | $3,804 |
| Ibandronate Sodium | 78 | $2,319 |
| Allopurinol | 141 | $1,493 |
| Alendronate Sodium | 128 | $1,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $7,718 | $191,19426 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $24 | $3,80456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 22 rheumatology providers in Rhode Island.
Other rheumatology in Cranston
- Jack MouradCranston$4K
- Matthew WhiteCranston$306
- Edward ReardonWarwick$403K
- Jay ToderJohnston$139K
- Anthony ReginatoE. Providence$109K
- David KadmonLincoln$13K
- Christopher D ArcyWesterly$7K
- Vinit Joseph GilvazPawtucket$4K
- Wendy SilversmithWesterly$3K
- Edward LallyE. Providence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.